W(h)ither metreleptin for lipodystrophy and the metabolic syndrome?

Endocrine Practice

Volumn 16, Issue 2, 2010, Pages 162-166

  Mantzoros, Christos S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; LEPTIN; METRELEPTIN; PLACEBO; UNCLASSIFIED DRUG; DRUG DERIVATIVE;

DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; EDITORIAL; HIV HIGHTLY ACTIVE ANTIRETROVIRAL THERAPY ASSOCIATED LIPODYSTROPHY AND METABOLIC SYNDROME; HORMONE SUBSTITUTION; HUMAN; IMMUNOMODULATION; INSULIN RESISTANCE; LIPODYSTROPHY; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; PATHOGENESIS; TREATMENT INDICATION; CONGENITAL GENERALIZED LIPODYSTROPHY; GENETICS; METHODOLOGY; NOTE; PATHOLOGY;

HORMONE REPLACEMENT THERAPY; HUMANS; LEPTIN; LIPODYSTROPHY; LIPODYSTROPHY, CONGENITAL GENERALIZED; METABOLIC SYNDROME X;

EID: 77953935732     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP10038.ED     Document Type: Editorial

References (33)

1. Gao C, Mantzoros CS. Lipodystrophy syndromes. In: Jameson JL, De Groot LJ, eds. Endocrinology. 6th ed. Philadelphia, PA: Elsevier, Mosby, Saunders, 2010. In press.
2. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62. (Pubitemid 40075680)
3. Leow MK, Addy CL, Mantzoros CS. Clinical review 159: human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome; clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab. 2003;88:1961-1976. (Pubitemid 36549862)
4. Chan JL, Oral EA. Clinical classification and treatment of congenital and acquired lipodystrophy. Endocr Pract. 2010;16:310-323.
5. Savage DB, O'Rahilly S. Leptin therapy in lipodystrophy. Diabetologia. 2010;53:7-9.
6. Gavrilova O, Marcus-Samuels B, Graham D, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest. 2000;105:271-278. (Pubitemid 30094446)
7. Rodeheffer MS, Birsoy K, Friedman JM. Identification of white adipocyte progenitor cells in vivo. Cell. 2008;135:240-249.
8. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 1999;401:73-76.
9. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941-946. (Pubitemid 32756432)
10. Addy CL, Gavrila A, Tsiodras S, et al. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab. 2003;88:627-636. (Pubitemid 36207802)
11. Nagy GS, Tsiodras S, Martin LD, et al. Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis. 2003;36:795-802. (Pubitemid 36337987)
12. Lee JH, Chan JL, Sourlas E, Raptopoulos V, Mantzoros CS. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab. 2006;91:2605-2611. (Pubitemid 44024625)
13. Gavrila A, Hsu W, Tsiodras S, et al. Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial. Clin Infect Dis. 2005;40:745-749. (Pubitemid 40381352)
14. Mantzoros CS. Whither recombinant human leptin treatment for HIV-associated lipoatrophy and the metabolic syndrome? J Clin Endocrinol Metab. 2009;94:1089-1091.
15. Mulligan K, Khatami H, Schwarz JM, et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab. 2009;94:1137-1144.
16. Brennan AM, Lee JH, Tsiodras S, et al. r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans. Eur J Endocrinol. 2009;160:173-176.
17. Stanley TL, Grinspoon SK. GH/GHRH axis in HIV lipodystrophy. Pituitary. 2009;12:143-152.
18. Javor ED, Moran SA, Young JR, et al. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metab. 2004;89:3199-3207. (Pubitemid 38951884)
19. Park JY, Javor ED, Cochran EK, DePaoli AM, Gorden P. Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. Metabolism. 2007;56:508-516. (Pubitemid 46427848)
20. Oral EA, Chan JL. Rationale for leptin-replacement therapy for severe lipodystrophy. Endocr Pract. 2010;16:324-333.
21. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002;110:1093-1103. (Pubitemid 35215890)
22. Matarese G, Moschos S, Mantzoros CS. Leptin in immunology. J Immunol. 2005;174:3137-3142. (Pubitemid 40354011)
23. Papathanassoglou E, El-Haschimi K, Li XC, Matarese G, Strom T, Mantzoros C. Leptin receptor expression and signaling in lymphocytes: kinetics during lymphocyte activation, role in lymphocyte survival, and response to high fat diet in mice. J Immunol. 2006;176:7745-7752. (Pubitemid 43849075)
24. Chan JL, Wong SL, Orlova C, Raciti P, Mantzoros CS. Pharmacokinetics of recombinant methionyl human leptin after subcutaneous administration: variation of concentration-dependent parameters according to assay. J Clin Endocrinol Metab. 2007;92:2307-2311. (Pubitemid 46997138)
25. Himanshu M, Bhat CB, Ramchandran S, Bhat KG, Kumar PK. Immunogenicity of human and bovine insulin in type 1 diabetes mellitus patients. Diabetes Technol Ther. 2008;10:305-309.
26. Fireman P, Fineberg SE, Galloway JA. Development of IgE antibodies to human (recombinant DNA), porcine, and bovine insulins in diabetic subjects. Diabetes Care. 1982;5(suppl 2):119-125. (Pubitemid 13251457)
27. Massa G, Vanderschueren-Lodeweyckx M, Bouillon R. Five-year follow-up of growth hormone antibodies in growth hormone deficient children treated with recombinant human growth hormone. Clin Endocrinol (Oxf). 1993;38:137-142. (Pubitemid 23042721)
28. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative review: the role of leptin in human physiology; emerging clinical applications. Ann Intern Med. 2010;152:93-100.
29. Welt CK, Chan JL, Bullen J, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med. 2004;351:987-997. (Pubitemid 39166262)
30. Brennan AM, Mantzoros CS. Drug insight: the role of leptin in human physiology and pathophysiology - emerging clinical applications. Nat Clin Pract Endocrinol Metab. 2006;2:318-327. (Pubitemid 43885911)
31. Chan JL, Heist K, DePaoli AM, Veldhuis JD, Mantzoros CS. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest. 2003;111:1409-1421. (Pubitemid 36554712)
32. Chan JL, Mantzoros CS. Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa. Lancet. 2005;366:74-85. (Pubitemid 40956533)
33. Rosenbaum M, Goldsmith R, Bloomfield D, et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest. 2005;115:3579-3586. (Pubitemid 43121846)